Zhang HY, Guo JH, Gao S, Chen H, Wang XD, Zhang PJ, Liu P, Cao G, Xu HF, Zhu LZ, Yang RJ, Li J, Zhu X. Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy. World J Gastrointest Oncol 2018; 10(11): 431-438 [PMID: 30487954 DOI: 10.4251/wjgo.v10.i11.431]
Corresponding Author of This Article
Xu Zhu, MD, Assistant Professor, Associate Professor, Doctor, Staff Physician, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing 100142, China. drzhuxu@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Zhang HY, Guo JH, Gao S, Chen H, Wang XD, Zhang PJ, Liu P, Cao G, Xu HF, Zhu LZ, Yang RJ, Li J, Zhu X. Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy. World J Gastrointest Oncol 2018; 10(11): 431-438 [PMID: 30487954 DOI: 10.4251/wjgo.v10.i11.431]
Hang-Yu Zhang, Cancer Biotherapy Centre, the First Affiliated Hospital of Zhejiang University, Hangzhou 310003, Zhejiang Province, China
Jian-Hai Guo, Song Gao, Hui Chen, Xiao-Dong Wang, Peng-Jun Zhang, Peng Liu, Guang Cao, Hai-Feng Xu, Lin-Zhong Zhu, Ren-Jie Yang, Jian Li, Xu Zhu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, Beijing 100142, China
Author contributions: Li J and Zhu X designed the research; Zhang HY, Guo JH, Gao S, Zhang PJ and Chen H analyzed the data; Zhang HY wrote the paper; Wang XD, Yang RJ and Zhu X critically revised the manuscript for important intellectual content; Li J and Zhu X contributed equally to this work and should be considered co-first authors.
Supported byCapital Foundation of Medical Development (China), No. 2014-2-2154.
Institutional review board statement: This study has a statement on ethics approval by the Medical Ethics Committee of Beijing Tumor Hospital, which is a part of Beijing Cancer Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that was obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: We have no financial relationships to disclose.
Data sharing statement: The datasets generated during the current study are not publicly available due to usage in another ongoing study, but are available from the corresponding author upon reasonable request.
Correspondence to: Xu Zhu, MD, Assistant Professor, Associate Professor, Doctor, Staff Physician, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Interventional Therapy, Peking University Cancer Hospital and Institute, No.52 Fucheng Road, Haidian District, Beijing 100142, China. drzhuxu@163.com
Telephone: + 86-10-88196330 Fax: +86-10-88196330
Received: August 7, 2018 Peer-review started: August 8, 2018 First decision: September 12, 2018 Revised: September 19, 2018 Accepted: October 12, 2018 Article in press: October 12, 2018 Published online: November 15, 2018 Processing time: 100 Days and 10.5 Hours
Abstract
AIM
To analyze the survival data between patients diagnosed with right-sided primary (RSP) tumors and patients diagnosed with left-sided primary (LSP) tumors after hepatic arterial infusion chemotherapy (HAIC) at our center.
METHODS
A retrospective analysis of pretreated metastatic colorectal cancer patients who received HAIC from May 2006 to August 2015 was conducted. A Cox proportional hazard regression analysis was used to assess the long-term survival outcomes. The mean and median age of patients was 61 years (range 27-85 years). There were 115 males and 53 females in our study.
RESULTS
One hundred sixty-eight patients were enrolled in this study. The overall response rate was 28.9% in LSP patients and 27.3% in RSP patients. The disease control rate was 76.3% in LSP patients and 69.7% in RSP patients. The median overall survival in response to HAIC was 16.3 mo in the LSP arm and 9.3 mo in the RSP arm (P = 0.164). The median progression-free survival was 5.7 mo in the LSP arm and 4.2 mo in the RSP arm (P = 0.851).
CONCLUSION
There was no significant difference in survival between LSP patients and RSP patients after HAIC. Further prospective studies are needed to confirm these findings.
Core tip: Our study shows that the prognosis of left-sided colorectal cancer liver metastasis patients is superior to that of right-sided patients, but no significant difference in survival was found between left-sided primary and right-sided primary patients in response to treatment with hepatic arterial infusion chemotherapy.
